AHA Guidelines for Myocarditis
Treat myocarditis presenting as dilated cardiomyopathy with standard guideline-directed heart failure therapy, avoid NSAIDs and competitive sports for 3-6 months, and reserve immunosuppression only for specific histologic subtypes (giant cell, eosinophilic, or cardiac sarcoidosis)—not for routine acute lymphocytic myocarditis. 1
Diagnostic Approach
The AHA recommends a structured diagnostic workup for all patients with clinically suspected myocarditis:
Mandatory Initial Testing
- Cardiac troponin levels - essential for diagnosis 1
- 12-lead ECG - perform in all suspected cases 1
- Transthoracic echocardiography - standard imaging for all patients 1
Clinical Presentations to Recognize
Look for these specific patterns 1:
- Acute chest pain (pericarditic or pseudoischemic)
- New or worsening dyspnea (days to 3 months)
- Palpitations, syncope, or aborted sudden cardiac death
- Unexplained cardiogenic shock
- New arrhythmias or conduction abnormalities
When to Perform Endomyocardial Biopsy (EMB)
EMB is indicated only in high-risk presentations 1:
- Patients requiring inotropic support or mechanical circulatory support
- Mobitz type 2 second-degree or higher heart block
- Sustained or symptomatic ventricular tachycardia
- Failure to respond to guideline-based therapy
The AHA acknowledges disagreement with ESC guidelines—the AHA takes a more restrictive approach to EMB compared to ESC's broader recommendations 1.
Treatment Strategy
Standard Management for All Patients
Heart failure therapy - Follow current systolic heart failure guidelines for myocarditis presenting as DCM 1
Critical restrictions:
- Avoid NSAIDs - increases inflammation and mortality risk 1
- Avoid competitive sports for 3-6 months - sustained aerobic exercise during acute viral myocarditis increases mortality in animal models and can cause sudden death 1
- Require clinical evaluation and functional testing before resuming competitive sports 1
Immunosuppression: When NOT to Use It
Do NOT use immunosuppression for acute lymphocytic myocarditis in adults - individual trials and meta-analyses show it is generally not indicated 1
Immunosuppression: When to Consider It
Consider immune-modulating therapy only for these specific subtypes 1:
- Giant cell myocarditis
- Cardiac sarcoidosis
- Eosinophilic myocarditis
Arrhythmia Management
- Acute arrhythmias - supportive management only, as arrhythmias typically resolve with inflammation resolution 1
- Drug-refractory ventricular arrhythmias - endocardial and epicardial radiofrequency catheter ablation can be effective 1
Advanced Therapies
Mechanical circulatory support (MCS):
- Required for cardiogenic shock despite optimal medical management 1
- Some patients can be bridged to recovery
- Role of immunosuppression in MCS patients remains uncertain and unstudied 1
Cardiac transplantation:
- Overall survival similar to other causes of cardiac failure in adults 1
- Caution in children - higher post-transplant risk if active myocarditis present in explanted heart 1
Common Pitfalls to Avoid
- Do not give NSAIDs - despite chest pain, these worsen outcomes
- Do not allow early return to sports - even if patient feels better, wait minimum 3-6 months with reassessment
- Do not routinely immunosuppress - only specific histologic subtypes benefit
- Do not delay MCS - in fulminant presentations, early mechanical support is critical 2
Etiology Considerations
In North America and Western Europe, viral infections are the most common cause 1. The AHA emphasizes obtaining careful travel and exposure history, as regional causes vary (Chagas disease, post-streptococcal disease, HIV in specific regions) 1.